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Pharmacogenetics: A reality or misplaced optimism? 
 
 
 Accessible summary  
 Evidence from research relating to the way genes affect medication effectiveness and 
side effects is reviewed.  Currently, there is strong evidence suggesting that drug response varies across 
individuals and this is particularly so across racial and ethnic lines. These differences 
are genetically determined  There is hope that in future; an individual’s genetic information can be used to help to 
decide which drug is effective for which person and at what dose before treatment.  
 
Abstract  
The paper aims to review current evidence that support the application of genetic information 
in the management and use of psychotropic medication. Although the importance of an 
individual’s genetic makeup in the metabolism of drugs has been known for at least 50 years, 
it is only recently that such information is finding clinical application. A literature review of 
recent studies suggests that there are clear variations in the way people respond to 
psychotropic medication. These variations can be seen across racial and ethnic lines and, are 
genetically determined. The hope is that, in future we will be able use genetic information to 
predict which patient will benefit from which drug and at what dose. In other fields of 
healthcare such as anticoagulant therapy, the application of pharmacogenetics is now 
established in routine clinical care. Several psychiatric pharmacogenetic tests are currently 
available, including tests for the determination of metabolic status, risk of agranulocytosis 
and metabolic syndrome, and selection of beneficial medications. Since nurses are the 
centrepiece of mental health care, these advances are likely to alter significantly future mental 
health  nurse education and  practice.   
Introduction  
The role of psychotropic medication in the treatment and recovery of people with mental 
health problems is well recognised in spite of other treatment modalities. Moreover it has 
been demonstrated that service users place a high importance on the use of medication to aid 
recovery (Piat et al. 2009). Despite this recognition, debate still exists as to their effectiveness 
for a number of reasons. From a safety perspective, psychotropic medication and 
antipsychotics in particular presents a considerable risk both in terms of the way they interact 
with each other and overdose. In addition, there is an alarming abuse of inappropriate 
psychotropic drug consumption worldwide with the use of polypharmacy being a typical 
example(Barnes and Paton 2011). The modest efficacy profile and substantial safety risk of 
psychotropic medication poses considerable challenges for mental health care. In mental 
health nursing, it has been argued that nurses lack adequate knowledge of 
psychopharmacology and this has resulted in nurses giving suboptimal advice to service 
users. (Latter et al. 2000; Kaas et al. 2000; Jordan et al. 1999; Skingsley et al. 2006). 
Inadquate knowledge almost always leads to suboptimal care of patients and this is clearly 
demonstrated in Latter et al (2000) study. In their study, the investigators found that nurses’ 
contribution to medication education for patients was frequently limited to giving simple 
information i.e. giving the name of medication, purpose, colour of tablet and the number of 
times, it is to be taken. In many respects, this inadquate knowledge is due to the shift away 
from a biological to a social science model of nursing care which has resulted in a reduction 
in pharmacological knowledge and this has had important ramification for nurses at pre and 
post registration level(Cooper et al. 2008). In particular there is evidence to suggest this 
inadquade undestanding of pharmacology has negatively and significantly impacted on nurse 
prescribing training where pharmacology is a critical component of the course (Meade et al. 
2009). In mental health nursing, this problem assumes a greater importance due to the recent 
growth in medication options and the increasing complexity of pharmacological decision 
making process. This is particularly critical especially for mental health nurse prescribers 
where inadequate understanding of psychopharmacology has been reported (Skingsley et al. 
2006).  
In recognition of the above, the NMC have developed the Essential Skills Cluster (ESC) in 
which Medicines Management is one such skill. As from September 2008 it has been a 
mandatory requirement that all student nurses demonstrate competency in medicines 
management at the point of registration. Specifically, ESC 36 states that, “People can trust 
the newly registered graduate nurse to ensure safe and effective practice in medicines 
management through comprehensive knowledge of medicines their actions, risks and 
benefits”. This stand is clearly underpinned by the reality that in many mental health settings, 
it is the mental health nurse who is responsible for administering medication. It is also the 
mental health nurse who should be alert to adverse medication reaction and take steps to 
minimize side effects. Moreover, it is the mental health nurse who is responsible for co-
coordinating treatment modalities and integrates drug treatments with a variety of essential 
treatments in a way that is safe and acceptable to the patient.  
Patient’s response to medication and safety is likely to be dramatically altered by the 
integration of genetic information during the treatment process. These advances have the 
potential to alter significantly the way in which mental health nurses practice or deliver care.  
 
This article reviews the progress made in research toward understanding how genetic factors 
influence psychotropic drug responses. As in any new field of research, there are challenges 
that lie ahead in translating the research findings into clinical practices that yield tangible 
benefits for patients with mental health problems. This review begins by discussing the 
importance of pharmacogenetics in healthcare before explaining the relationship between 
genetic variation and drug response. The link between antipsychotics, antidepressants, mood 
stabilisers and genetic variation will be reviewed and finally, the clinical implication of 
pharmacogenetics will be discussed.  
 
The importance of pharmacogenetics  
Pharmacogenetics is the science dedicated to the identification of genes influencing response 
to medication. It had a clear breakthrough in the 1950s with the discovery that the 
antihypertensive drug debrisoquine showed inheritable patterns of metabolism. Since then, 
pharmacogenetic research has expanded to cover most fields in medicine, acquiring special 
importance in complex diseases, including psychiatric illnesses (Arranz and Kapur 2008). As 
previously acknowledged, the effectiveness of current psychotropic drugs in clinical practice 
is suboptimal and they are effective in only a proportion of patients or produce partial 
response in other patients. Additionally, they are usually associated with adverse side effects 
that impact negatively on adherence and quality of life. More importantly, most of these 
drugs were not developed based on an understanding of the pathophysiology of the illnesses 
being treated and this has important ramifications in the treatment response and recovery of 
patients.  
Pharmacogenetics research has established that drug response varies across racial and ethnic 
lines. For example, current evidence among other findings suggests that Chinese people can 
be treated with antipsychotic doses that are significantly lower than their Caucasian 
counterparts (Lin et al., 1988). This variable response to psychotropic medication has been 
attributed to the way genes influence individual metabolism of drugs. There is growing 
optimism that pharmacogenetics will ultimately provide the right drug to the right person for 
the right illness in the right dose. To better understand the role of genetic factors we need to 
review the link between genes, enzymes and metabolism of drugs.  
How does genetic variation affect drug response? 
Drugs given to a patient usually enter the blood circulation after absorption into the blood 
stream. From the blood stream, the drug is distributed throughout the body including the 
brain and then broken down (metabolised) mostly in the liver before it is eliminated from the 
body mostly through the kidneys. The rate at which the drug is broken down by the liver 
affects its concentration in the blood circulation. A slow rate of metabolism results in higher 
concentration of the drug in the blood circulation. A higher concentration of the drug in the 
blood typically leads to heightened adverse side effects. A fast rate of metabolism, on the 
other hand, leads to low concentration of the drug in blood making it less effective. So, what 
affects the rate of metabolism of a drug? The answer is enzymes.  
Enzymes are proteins found in both animals and plants, which act as organic catalysts. They 
help chemical reactions such as drug metabolism to proceed quickly and efficiently. Whether 
a drug has a pharmacological (beneficial) or toxicological (harmful) effect largely depends on 
its metabolism and therefore on enzymes. The enzymes responsible for controlling drug 
metabolism are found mostly in the liver and are called Cytochrome P450 enzymes. The 
production of CYP enzyme is controlled by genes (one gene-one enzyme) and genetic 
mutation give rise to different versions of a CYP enzyme. This variation is called 
pharmacogenetic polymorphism (literally, ‘many forms’) and is more pronounced across 
racial groups. This pharmacogenetic polymorphism partly explains why medicine response 
varies across people, especially across racial groups.  
 
Pharmacogenetic polymorphism divides the population into at least three types of responders. 
The first group is those people with a gene variant (allele) that is not working or missing. 
These people are called poor metabolisers. Poor metabolisers biotransform medicines more 
slowly than average, resulting in higher concentration of the drug in the blood circulation. In 
practice poor metabolisers require lower doses of the drug to achieve a therapeutic effect and 
they are prone to adverse side effects. In other words, poor metabolism is seen in people who 
have the genetic inability to metabolise a drug efficiently. For example, 33 percent of African 
Americans and 37 percent of Asians are slow metabolisers of several antipsychotic 
medications and antidepressants (Lin et al., 1997). The second group is those with an allele 
that is functioning normally, and they are called extensive metabolisers. Extensive 
metabolisers are able to biotransform a medicine at a normal and expected rate and therefore 
in practice, require the recommended dose of the drug. The third group have an allele that is 
very fast at metabolising a drug and they are called ultra-extensive metabolisers. These 
people biotransform a drug at a much higher rate than most people, and in practice will need 
a higher medicine dose to achieve therapeutic effect. In Physical Medicine for example, 
tamoxifen is known to be less effective in non white patients because non white patients tend 
to be ultra extensive metabolisers of this drug. With respect to psychotropic medication, there 
is evidence suggesting different types of psychotropic medication are metabolised differently 
in different people including racial groups.  
 
[B]  Antipsychotics 
It is well known that there is wide variability in clinical response and adverse side effects 
tolerability of antipsychotic medications in individuals. Typical antipsychotics like 
haloperidol are effective in about 70% of the patients in predominantly alleviating positive 
symptoms like delusions and hallucinations (Wilffert et al. 2005). They are also limited in 
their use because they induce adverse side effects and are less effective in treating negative 
symptoms. On the other hand, atypical antipsychotics usually treat both positive and negative 
symptoms but patients show heterogeneity in their response to treatment. This variation is 
supported by promising evidence from epidemiological and pharmacogenetics studies that 
suggest a strong link between drug response and genetics (Foster et al. 2010).Since the 
middle of 1990s, hundreds of studies of pharmacogenetics of antipsychotic drugs have been 
published, making it a rapidly growing research area. Twin and family studies suggest that 
response to antipsychotics medication is a heritable trait. Studies of single pairs of 
monozygotic twins observed similar response to treatment with antipsychotics (Mata et al. 
2001; Vojvoda et al. 1996) and have similar levels of drug induced weight gain(Wehmeier et 
al. 2005). Studies of siblings and first-degree relatives have demonstrated similar levels of 
treatment-induced tardive dyskinesia (TD), movement disorders, and response to 
medications. There is also preliminary evidence to suggest that the side-effect profiles of 
second-generation antipsychotic medications and their propensity to cause weight gain, 
glucose and lipid abnormalities as well as tardive dyskinesia is related to genetic 
factors(Patsopoulos et al. 2005).  Such knowledge has clinical application that will ultimately 
drive choices of antipsychotic medication based on the likelihood of clinical response and 
development of side effects in light of a particular patient's genetic profile. This is 
particularly so in different ethnic and racial groups, where clear differences in antipsychotic 
response have been consistently noted (Wolinsky 2011; Burroughs et al. 2002). For example, 
an early study found that when given comparable doses of medication, Chinese patients with 
schizophrenia and Chinese normal volunteers showed  plasma haloperidol concentrations that 
were approximately 50% greater than their Caucasian counterparts (Lin et al. 1988). At the 
same time, the study showed a greater prolactin response to haloperidol in Chinese than 
Caucasians. Recent studies (Subramaniam et al. 2007)  have supported earlier findings. In a 
study that examined metabolic disturbances in different ethnic groups Subramaniam et al 
(2007) found that there were no ethnic differences in the mean plasma clozapine 
concentration between Asian and Caucasian despite Asians being prescribed lower doses of 
clozapine. However, Caucasian patients suffered more metabolic disorders than Asian 
patients. In the UK, clozapine is used much less among African-Caribbean patients than other 
ethnic minorities (Mallinger and Lamberti 2006). Lower normal ranges for white blood cell 
counts in these patients (benign ethnic neutropenia) may partly explain this discrepancy that 
has also been observed in Middle-Eastern ethnic groups. Ashkenazi Jews also appear to have 
an increased susceptibility to clozapine-induced agranulocytosis (Whiskey and Taylor 2007). 
The cross ethnic variation to antipsychotic is now supported by a recent meta-analysis that 
has found that the gene variant Gly9 is associated with a significantly higher risk of 
developing tardive dykinesia in people of Chinese origin than Caucasians (Bakker et al. 
2006). This provides a clear example of the potential clinical application of pharmacogenetic 
information, especially when combined with relevant environmental and clinical information. 
In many respects, the relationship between a person genetic and how they respond to 
antipsychotics mirrors the relationship between genetics and antidepressants. 
 
Antidepressants 
In the ground breaking and recently completed Sequenced Treatment Alternative to Relieve 
Depression(STAR*D) study, in which patient with major depression were followed for up to 
6 years, only 37% achieved remission on first line therapy and a further 16% withdrew after 
suffering adverse drug effects (Zandi and Judy 2010). Up to 60% of depressed patients did 
not respond completely to antidepressants and up to 30% did not respond at all. It is 
estimated that genetic factors accounted for as much as 50% of antidepressant response 
(Crisafulli et al. 2011). Clearly, antidepressants do not work as well for everyone and this is 
true for psychotropic medication in general. With respect to Serotonin Reuptake Inhibitors 
(SSRI), although they have quickly gained popularity and are the most widely used 
antidepressants, they like any other psychotropics, are only effective in a subset of patients 
and are associated with certain adverse side effects .such as weight gain and sexual 
dysfunction. One serotonin allele that has been identified as a “target gene” is the serotonin 
transporter gene (SLC6A4) which has alleles that have been shown to influence clinical 
response in Caucasians treated with SSRIs(Zandi and Judy 2010). In general, huge 
differences in the way antidepressant drugs are metabolised in different individuals have been 
consistently shown across many types of antidepressants.  
 
In terms of race and ethnicity, there are key differences across ethnic groups in the way 
people respond to antidepressants. Recently, two meta-analyses of pharmacogenetic studies 
of antidepressants have reported associations between some serotonin gene variants and 
treatment response (Serretti et al. 2007). In their meta analysis of 15 studies, Serretti et al 
(2007) found that one serotonin allele was associated with better treatment response and 
better remission rates. In the second meta-analysis of, 9 studies found, that the same gene 
variant was also associated with reduced side effects profile in patients(Kato and Serretti 
2010). In addition, it is known that CYP2D6 enzyme that is abundant in the liver and is 
involved in the metabolism of many psychotropic medications including antidepressants is 
associated with a tendency to develop toxic reactions. Therefore, individuals who use the 
CYP2D6 to metabolise psychotropics are likely to develop extrapyramidal side effects and 
weight gain (Arranz and Kapur 2008). The distribution of CYP2D6 allele varies 
geographically, with up to 10% of Caucasians and up 2% of Asians using this gene variant to 
metabolise psychotropics. Similar cross ethnic variation has been observed with other CYP 
enzymes and some candidate-genes have already been identified, showing promising results 
(Monnin et al. 2009).  
  
With respect to tricyclic antidepressants for example, early studies have reported that 
Caucasians appear to have lower plasma levels of tricyclic antidepressants and attain plasma 
peaks later when compared with Asians from the Indian subcontinent(Rudorfer et al. 1984). .  
These differences have been attributed to a greater incidence of slower pharmacokinetics 
among Asians compared with Caucasians. Mood stabilisers like all psychotropic drugs are 
influenced by genetics in their metabolism. 
 
Mood stabilisers  
Carbamazepine is a widely used drug for the treatment of epilepsy and is a mood stabiliser. In 
rare cases, carbamazepine causes life threatening hypersensitivity reactions, including 
Stevens– Johnson syndrome. The risk of these events is estimated to be  up to six per 10,000 
new users in countries with mainly Caucasian populations and the risk multiplies tenfold in 
Asian populations(Lim et al. 2008; Farkas 2007). A striking genetic association with 
carbamazepine was detected in a sample of Han Chinese in Taiwan, where a gene 
variant(HLA-B*1502) was present (Lim et al. 2008). In this sample, 100% of people who 
suffered carbamazepine-induced Stevens Johnson Syndrome, had this gene variant compared 
to only 3%  who had other gene variants (Chung et al. 2004).. These findings were replicated 
in subsequent series across Asia (Mehta et al. 2009; Hung et al. 2006; Locharernkul et al. 
2008) but not in Caucasians (Lonjou et al. 2006). Based on these studies some  regulatory 
bodies including the European Medicines Agency and the US Food and Drug Administration 
recommend HLA genetic testing in at-risk populations such as Chinese prior to initiating 
carbamazepine therapy(Ferraldeschi and Newman 2011). 
 
Implications of pharmacogenetics in mental health practice  
The main clinical application of pharmacogenetics is to be able to predict which patient will 
benefit from which drug based on genetic information. The clinical utility of this science is 
evolving and this should facilitate delivery of individually tailored treatment to maximize 
treatment response and minimise adverse drug induced side effects. Clearly, this is in line 
with the Recovery Approach principles. In the area of antipsychotic drug treatment, research 
from the past two decades has provided converging evidence that several genetic 
polymorphisms are capable of predicting treatment response or adverse drug-induced effects. 
These findings have been replicated in a number studies, in various ethnic groups and 
different medications (Zhang and Malhotra, 2011). Since most of the variation comes in the 
form of inactivation or reduction in activity in the enzymes, the result is higher amounts of 
medication in the blood, triggering untoward side effects. This awareness should lead to more 
cautious prescribing practices, which usually mean starting patients at lower doses in the 
beginning of treatment. Unfortunately, just the opposite is true for some ethnic minority 
groups. The combination of slow metabolism and overmedication of antipsychotic drugs in 
people of African or Chinese descent can yield very uncomfortable extrapyramidal side 
effects. (Sussman et al. 1987) have asserted that these are the kinds of experiences likely to 
contribute to the mistrust of mental health services reported by some ethnic minority groups. 
Greater awareness of the role of pharmacogenetics is expected to improve treatment 
effectiveness in psychiatry. However, a number of issues need to be resolved before 
pharmacogenetic findings can be meaningfully applied to clinical practice and this  is clearly 
evidenced by the licensing of Isosorbide Dinitrate and Hydralazine hcl( BiDil).  
In the USA, the Food and Drug Administration (FDA)’s approved BiDil, as the first drug to 
be licensed for a specific ethnic population, namely self-identified blacks. However, BiDil 
remains mired in controversy over race-based medicine. This controversy has played out 
mainly in the USA but has important implications worldwide for the future of personalised 
medicine. There is compelling evidence of BiDil’s efficacy (Senguin et al., 2008). No other 
drug combination has been shown, under similar circumstances, to have such a large survival 
advantage, and improvement in time to first hospitalization and quality of life in African 
Americans with heart failure (Seguin et al. 2008). However, the problematic nature of racial 
classification has generated heated debate as to the clinical utility of pharmacogenetics 
(Duster 2007). Physical traits commonly associated with “racial groups” such as skin colour, 
facial features are superficial to the response to drugs and therefore race is an imprecise 
proxy measure of these genetic differences (Burroughs et al. 2002). The picture is further 
complicated by the well-documented contribution of environmental, clinical, and 
demographic factors, which are difficult to study.  
 
In reality, race and ethnicity should be considered along with cultural and environmental 
factors such as age gender, diet, smoking, family influence, climate and pollutants to name a 
few. These factors may operate independently or interactively. However, in spite of the role 
of environmental and cultural factors in drug response and tolerability, it is still generally 
accepted that genetic factors are the major biological determinants of drug response and 
responsible for many differences in pharmacological activity among patients. They may 
account for 60–90% of drug variability in drug disposition and pharmacodynamics and for 
this reason, the clinical utility of pharmacogenetics is obvious (Cacabelos and Martinez-
Bouza 2010). Prescribers can obtain genetic information along with all other factors that help 
to predict the individual drug response before the start of treatment and use this information 
to select the most appropriate drug for the patient. Ideally, a combination of genetic and non 
genetic information should be used for the selection of appropriate treatment, but genetic 
testing can be useful on its own as a pre-treatment test. In this regard, there is a growing trend 
towards moving away from the concept of "one drug fits all" to a rather more individualized 
and personalized medicine. The goal is to define the appropriate drug dose that maximizes 
efficacy and minimizes toxicity in each individual patient. A good example of this is the role 
of the enzymeCYP2C9 genotyping in patients receiving oral anticoagulants.  
In spite of its inherent challenges, chronic oral anticoagulation with warfarin is difficult to 
maintain within the therapeutic range and requires frequent monitoring and dose adjustments. 
This is due to genetically derived variation in metabolism of warfrin. Recent studies suggest 
that the pharmacogenomics-guided dosing algorithm can accurately predict warfarin dosage 
and might reduce adverse events (Ferraldeschi and Newman 2011). Therefore, incorporating 
pharmacogenetic testing or biomarker measurements into treatment algorithms has the 
potential to speed up recovery by shortening or eliminating current lengthy and at times 
ineffective trial and error approach. It is without doubt one of the most promising aspects of 
modern healthcare practice.  
In the future, this targeted approach (Wolinsky 2011) may become informative for 
prescribers choosing a psychotropic medication for an individual patient with mental health 
problems. This view is supported by a recent study by (Serretti 2011) that evaluated the 
benefit of pharmacogenetics in antidepressant treatment in a group of 100,000 patients with a 
current episode of major depressive disorder receiving citalopram or bupropion. The authors 
found that, genetic test use was associated with an increase in antidepressant response and 
better tolerability although the cost to benefit ratio was very high. However, a recent Danish 
study found no difference in cost between one psychiatric treatment centre that recommended 
genetic testing and another that did not (Herbild et al. 2011). In spite of these optimistic 
findings, other investigators have expressed caution before adopting routine genetic testing in 
clinical practice at this stage. Fleeman et al (2011) have carried out a systematic review of 47 
studies that examined the role of Cytochrome enzyme to consider whether testing for 
CYP450 polymorphisms in adults on antipsychotic treatment predicts and leads to 
improvements in clinical outcomes. Currently, the evidence supporting the role of CYP2D6 
polymorphisms in antipsychotic efficacy is inconclusive, although there is an association 
between CYP2D6 genotype and extrapyramidal adverse effects. The authors conclude that 
evidence supporting the clinical validity and utility of CYP2D6 testing in patients being 
prescribed antipsychotics is lacking, and thus, routine pharmacogenetic testing prior to 
antipsychotic prescription cannot be supported at present (Fleeman et al. 2011).  
 
Conclusion  
Technological advances have changed the nature of pharmacogenetic research and this has 
enormous implications on the future of healthcare in a general and that of mental health in 
particular. There is hope that drug treatment in future will be individualised, helping to 
minimize side-effects and identify patients sensitive or resistant to specific treatments. This is 
because in the last few decades, research has uncovered significant differences among people 
in the metabolism, clinical effectiveness, and side-effect profiles of many clinically important 
drugs including psychotropic medication (Barroughs et al., 2002). The full impact of these 
changes will take many years to unfold but genetic fingerprinting using DNA arrays is 
already practical. Ultimately, such approaches could drive choices of psychotropic 
medication based on the likelihood of clinical response and development of side effects in 
light of a particular patient's genetic profile. In the future, this targeted approach 
(personalized medicine) along with the influence of the public in agitating for better 
healthcare will have a profound effect on the ways mental health nurses deliver care that is 
orientated towards the Recovery Approach.  
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